BBP vs. VRAI
BBP (Virtus LifeSci Biotech Products ETF) and VRAI (Virtus Real Asset Income ETF) are both exchange-traded funds - BBP is a Health & Biotech Equities fund tracking the LifeSci Biotechnology Products Index, while VRAI is a REIT fund tracking the Indxx Real Asset Income Index. Both are passively managed. Over the past 5 years, BBP returned 13.91%/yr vs 6.30%/yr for VRAI. At a 0.41 correlation, their price movements are largely independent. BBP charges 0.79%/yr vs 0.55%/yr for VRAI.
Performance
BBP vs. VRAI - Performance Comparison
Loading charts...
Returns By Period
The year-to-date returns for both investments are quite close, with BBP having a 22.12% return and VRAI slightly higher at 22.69%.
BBP
- 1D
- -0.52%
- 1M
- 11.96%
- 6M
- 21.78%
- YTD
- 22.12%
- 1Y
- 56.48%
- 3Y*
- 22.51%
- 5Y*
- 13.91%
- 10Y*
- 13.09%
VRAI
- 1D
- 0.25%
- 1M
- -0.29%
- 6M
- 18.74%
- YTD
- 22.69%
- 1Y
- 23.84%
- 3Y*
- 11.09%
- 5Y*
- 6.30%
- 10Y*
- —
BBP vs. VRAI - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|---|---|---|
BBP Virtus LifeSci Biotech Products ETF | 22.12% | 33.15% | 3.32% | 17.88% | 0.85% | -8.17% | 22.24% | 7.83% |
VRAI Virtus Real Asset Income ETF | 22.69% | 6.67% | 2.66% | 6.12% | -9.96% | 24.35% | -5.94% | 6.05% |
Correlation
The correlation between BBP and VRAI is 0.15, which is low. Their price movements are largely independent, making them effective diversification partners.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.15 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.34 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.37 |
Correlation (All Time) Calculated using the full available price history since Feb 8, 2019 | 0.41 |
Over the past year, the correlation between BBP and VRAI has dropped to 0.15 - well below their long-term average of 0.41, suggesting their price drivers have been diverging.
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
BBP vs. VRAI — Risk / Return Rank
BBP
VRAI
BBP vs. VRAI - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Virtus LifeSci Biotech Products ETF (BBP) and Virtus Real Asset Income ETF (VRAI). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| BBP | VRAI | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | +0.34 | ||
| Sortino ratioReturn per unit of downside risk | +0.31 | ||
| Omega ratioGain probability vs. loss probability | 1.38 | 1.34 | +0.03 |
| Calmar ratioReturn relative to maximum drawdown | 6.12 | 4.97 | +1.15 |
| Martin ratioReturn relative to average drawdown | 18.80 | 15.05 | +3.75 |
Loading charts...
Drawdowns
BBP vs. VRAI - Drawdown Comparison
The maximum BBP drawdown since its inception was -44.32%, smaller than the maximum VRAI drawdown of -47.51%. Use the drawdown chart below to compare losses from any high point for BBP and VRAI.
Loading charts...
Drawdown Indicators
| BBP | VRAI | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -44.32% | -47.51% | +3.19% |
Max Drawdown (1Y)Largest decline over 1 year | -9.28% | -4.82% | -4.46% |
Max Drawdown (3Y)Largest decline over 3 years | -26.09% | -16.89% | -9.20% |
Max Drawdown (5Y)Largest decline over 5 years | -37.77% | -26.71% | -11.06% |
Max Drawdown (10Y)Largest decline over 10 years | -44.32% | — | — |
Current DrawdownCurrent decline from peak | -5.82% | -0.29% | -5.53% |
Average DrawdownAverage peak-to-trough decline | -11.93% | -9.97% | -1.96% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 3.02% | 1.60% | +1.42% |
Volatility
BBP vs. VRAI - Volatility Comparison
Virtus LifeSci Biotech Products ETF (BBP) has a higher volatility of 7.46% compared to Virtus Real Asset Income ETF (VRAI) at 3.57%. This indicates that BBP's price experiences larger fluctuations and is considered to be riskier than VRAI based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| BBP | VRAI | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 7.46% | 3.57% | +3.89% |
Volatility (6M)Calculated over the trailing 6-month period | 19.22% | 8.20% | +11.02% |
Volatility (1Y)Calculated over the trailing 1-year period | 24.21% | 11.92% | +12.29% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 26.44% | 16.59% | +9.85% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 27.36% | 22.01% | +5.35% |
BBP vs. VRAI - Expense Ratio Comparison
BBP has a 0.79% expense ratio, which is higher than VRAI's 0.55% expense ratio.
Dividends
BBP vs. VRAI - Dividend Comparison
BBP has not paid dividends to shareholders, while VRAI's dividend yield for the trailing twelve months is around 2.86%.
| Position | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
BBP Virtus LifeSci Biotech Products ETF | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.18% | 0.00% | 1.29% |
VRAI Virtus Real Asset Income ETF | 2.86% | 4.68% | 7.13% | 5.02% | 4.48% | 3.34% | 3.91% | 2.80% | 0.00% | 0.00% | 0.00% | 0.00% |
Frequently Asked Questions
BBP and VRAI have a correlation of 0.15, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
BBP has higher volatility (7.46%) compared to VRAI (3.57%). In terms of maximum drawdown, BBP dropped -44.32% vs VRAI's -47.51%.
On 5-year performance, BBP leads with 13.91% vs 6.30% for VRAI. On fees, VRAI is cheaper at 0.55% per year. On volatility, VRAI has been the lower-risk option at 3.57%. The better choice depends on whether you care most about return, fees, risk, or income.
Over the 5-year period, BBP has performed better with a 13.91% return vs 6.30%. Past performance does not guarantee future results, so compare this with risk, fees, and fund exposure.
VRAI is cheaper with a 0.55% expense ratio, compared with 0.79% for BBP.
VRAI has the higher dividend yield at 2.86%, compared with 0.00% for BBP.
BBP is categorized as Health & Biotech Equities, while VRAI is REIT. BBP tracks LifeSci Biotechnology Products Index, while VRAI tracks Indxx Real Asset Income Index. Their fees differ too: 0.79% for BBP and 0.55% for VRAI.
BBP currently has the higher Sharpe Ratio (2.35 vs 2.01), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for BBP and VRAI
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer